Values as of: 2024-09-18
COMMON STOCK | Medical Distribution |
Last Closing
USD 0.6Change
-0.05 (-7.69)%Market Cap
USD 0.05BVolume
0.15MAnalyst Target
USD 12.10Verdict
Verdict
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates in two segments, B2C and B2B. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services that include online consultation services and electronic prescription services to consumers. It offers prescription and over-the counter drugs, including western and traditional Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices comprising bandages and thermometers; and personal care products consisting of skin care, birth control, sexual wellness products, and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Pharmacy, which include pharmacies and wholesalers; and data and supply chain integration services. In addition, it offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. The company operates offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangdong, Guangzhou, Tianjin, and Kunshan. It serves pharmacies, pharmaceutical companies, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
Company Website : https://corporate.111.com.cn
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| HSIC | Henry Schein Inc |
+1.22 (+1.71%) |
USD 8.92B |
| PDCO | Patterson Companies Inc |
+0.22 (+1.01%) |
USD 1.93B |
| AHG | Akso Health Group ADR |
+0.15 (+15.82%) |
USD 0.22B |
| EDAP | EDAP TMS SA |
-0.07 (-2.22%) |
USD 0.12B |
| COSM | Cosmos Health Inc. |
-0.03 (-2.63%) |
N/A |
| ZYXI | Zynex Inc |
-0.01 (-0.12%) |
N/A |
N/A
| Market Performance vs. Industry/Classification (Medical Distribution) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -61.29% | 14% | F | 11% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -61.29% | 14% | F | 11% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -75.61% | 14% | F | 9% | A- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -75.61% | 14% | F | 9% | A- | ||
| Trailing 5 Years | |||||||
| Capital Gain | -86.81% | 33% | F | 13% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -86.81% | 33% | F | 12% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -12.72% | 29% | F | 23% | F | ||
| Dividend Return | -12.72% | 29% | F | 23% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 59.53% | 57% | F | 30% | F | ||
| Risk Adjusted Return | -21.38% | 14% | F | 28% | F | ||
| Market Capitalization | 0.05B | 20% | F | 29% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
The company has negative book value.
